• Sphene Capital cut Vidac Pharma's price target to EUR 3.80 from EUR 4.20 in a Nov. 11, 2026, research update.
• The firm maintained its Buy rating with a 36-month target horizon, reflecting revised development prospects and risks.
• Analysts viewed VDA-1102's Phase 2b actinic keratosis results as encouraging for further clinical development.
• Small patient numbers and baseline severity differences limited statistical interpretation, making the full clinical study report the next critical milestone.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vidac Pharma Holding plc published the original content used to generate this news brief via EQS News (Ref. ID: rc_27440) on November 11, 2026, and is solely responsible for the information contained therein.